Rangering i aksjer
#32234
Medicure Inc. is a biopharmaceutical firm focused on developing, researching,... Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Handel Medicure Inc. (MPH)
Pris MPH pris med markedsverdi på B
Markedsverdi av Medicure Inc.(MPH)
Markedsverdi: $10.65M
Per August 2026 har Medicure Inc. en markedsverdi på $10.65M. Dette gjør Medicure Inc. til det 32234th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Medicure Inc. fra 2012 til 2026
MPH sammenlignet med topp 5 mest populære stocks
| Pris på MPH |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.460T
|
+51,284,054.00%
|
|
|
|
|
$4.489T
|
+42,167,207.18%
|
|
|
|
|
$4.141T
|
+38,893,062.38%
|
|
|
|
|
$3.569T
|
+33,517,216.58%
|
|
|
|
|
$2.798T
|
+26,280,282.63%
|
